Dr. Brian A Van Tine, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Expert in Soft Tissue Sarcoma
Studies Cancer
49 reported clinical trials
67 drugs studied
About Brian A Van Tine, M.D., Ph.D.
Education:
- Earned an M.D. from the University of Texas Southwestern Medical Center in 2000.
- Obtained a Ph.D. in Cellular and Molecular Biology from the University of Texas Graduate School of Biomedical Sciences in 2000.
Experience:
- Has been an Assistant Professor of Medicine at Washington University School of Medicine since 2009.
- Serving as the Director of the Sarcoma Program at Siteman Cancer Center, Washington University School of Medicine, since 2015.
Area of expertise
1Soft Tissue Sarcoma
Global LeaderStage IV
Stage III
EWSR1/ATF1 positive
2Cancer
Stage IV
EWSR1/ATF1 positive
EWSR1/CREB1 positive
Affiliated Hospitals
Clinical Trials Brian A Van Tine, M.D., Ph.D. is currently running
ADI-PEG 20 + Chemotherapy
for Leiomyosarcoma
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Recruiting1 award Phase 310 criteria
APG-115 + Pembrolizumab
for Skin Cancer
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Recruiting1 award Phase 1 & 213 criteria
More about Brian A Van Tine, M.D., Ph.D.
Clinical Trial Related3 years of experience running clinical trials · Led 49 trials as a Principal Investigator · 16 Active Clinical TrialsTreatments Brian A Van Tine, M.D., Ph.D. has experience with
- Cyclophosphamide
- Nivolumab
- Placebo
- Temozolomide
- Pembrolizumab
- Dacarbazine
Breakdown of trials Brian A Van Tine, M.D., Ph.D. has run
Soft Tissue Sarcoma
Cancer
Lung Cancer
Uterine Leiomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian A Van Tine, M.D., Ph.D. specialize in?
Brian A Van Tine, M.D., Ph.D. focuses on Soft Tissue Sarcoma and Cancer. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Brian A Van Tine, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Brian A Van Tine, M.D., Ph.D. is currently recruiting for 14 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Brian A Van Tine, M.D., Ph.D. has studied deeply?
Yes, Brian A Van Tine, M.D., Ph.D. has studied treatments such as Cyclophosphamide, Nivolumab, Placebo.
What is the best way to schedule an appointment with Brian A Van Tine, M.D., Ph.D.?
Apply for one of the trials that Brian A Van Tine, M.D., Ph.D. is conducting.
What is the office address of Brian A Van Tine, M.D., Ph.D.?
The office of Brian A Van Tine, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.